Stereotactic Body Radiation Therapy for Patients With Lung Cancer Previously Treated With Thoracic Radiation

Kelly, Patrick; Balter, Peter A; Rebueno, Neal; Sharp, Hadley J.; Liao, Zhongxing; Komaki, Ritsuko; Chang, Joe Y.

doi:10.1016/j.ijrobp.2009.09.070

Cited by 149 publications

(150 citation statements)

References 26 publications

Supporting

Mentioning

134

Contrasting

Unclassified

Order By: Relevance

“…Anderson experience of SBRT for patients with lung cancer previously undergoing thoracic radiation. [29] In this study, 11 out of 36 patients had in-field local recurrence prior to SBRT as in our study. Their patients received 40 or 50 Gy in four fractions.…”

Section: Discussionmentioning

confidence: 77%

Salvage SBRT for Previously Irradiated Lung Cancer

Seung¹,

Solhjem²

2011

JCT

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 77%

Salvage SBRT for Previously Irradiated Lung Cancer

Seung¹,

Solhjem²

2011

JCT

View full text Add to dashboard Cite

show abstract

“…Only 11 of these patients were treated with SBRT for in-field failures. With 15 months of follow up, local control is 92% for the entire group [27] .…”

Section: Discussionmentioning

confidence: 94%

Stereotactic body radiotherapy (SBRT) for non- pathologically diagnosed lung cancer patients

Harkenrider¹,

Bertke²,

Dragun³

2012

JST

View full text Add to dashboard Cite

Objective: Medically inoperable patients with primary or recurrent lung cancer are increasingly being diagnosed clinically without pathologic confirmation especially for patients with comorbidities that preclude biopsy. The objective of this study is to report the outcomes of medically inoperable patients with unbiopsied primary or recurrent lung carcinoma with SBRT. From 2008From -2011 patients with non-pathologically diagnosed primary or recurrent lung cancer were treated with SBRT. All patients had diagnostic imaging clinically consistent with primary or recurrent lung malignancy. Fifteen patients had primary lung cancer and 7 had recurrent disease previously treated with surgery or fractionated radiotherapy. Median SBRT dose was 50 Gy (Range 40-55 Gy) in a median of 5 fractions (Range 4-10 fractions). Median BED was 100 Gy (Range 72-151.2 Gy). Methods:Results: Median follow up is 15.3 months (Range 6.6-33.0 months). Primary tumors had a median longest dimension on the original CT of 1.6cm, which enlarged to 2.0cm (P<0.001) on serial CT and decreased to 1.3cm (P=0.003) after SBRT. Recurrent tumors had a median longest dimension of 1.6cm, which increased to 2.7cm (P=0.33) on repeat CT and subsequently stabilized at 2.7cm after SBRT. On FDG-PET scan, median standard uptake value (SUV) for the entire population is 5.4 before SBRT which decreased to 2.3 (P<0.001) after treatment. For the entire population, absolute local control was 90.9%. Kaplan-Meier curves estimates at 2 years show regional control 100%, distant control 75%, cancer specific survival 92%, and overall survival 75%. There were no grade 3/4 acute or chronic treatment-related toxicities. Conclusions:In medically inoperable patients, a diagnosis of lung cancer can be provisionally made radiographically without pathologic confirmation. Local control can be achieved with minimal toxicity with the use of SBRT.

show abstract

“…SBRT has been integrated into salvage algorithms in patients with recurrent, locally advanced lung cancer at some centers [16] . Thirty-six patients had received prior thoracic radiotherapy.…”

Section: Discussionmentioning

confidence: 99%

Evaluating patterns of failure and salvage therapy for patients treated with primary stereotactic body radiation therapy for early stage non-small cell lung cancer

Mezera

Chandrasekhar

Kloecker

et al. 2014

JST

View full text Add to dashboard Cite

Objective: The purpose of this study is to evaluate patterns of failure after stereotactic body radiation therapy for early stage NSCLC and determine the role of salvage therapy on patient outcome.Methods: Eighty-two consecutive medically inoperable patients treated with definitive SBRT for early-stage NSCLC were examined. Ninety-four percent of patients had biopsy proven disease, the remainder refused. The median biologic effective dose (BED) for the cohort was 100 Gy (range, 78-180 Gy). Recurrence was defined clinically by RECIST and FDG-PET or by pathologic diagnosis. Results:The estimated median survival for the entire cohort was 29.2 months (range, 1 -40.3). The estimated 2 year overall survival (OS) was 65%. The 2 year local recurrence free survival, locoregional recurrence free survival and distant metastatic free survival were 89%, 78% and 72%, respectively. Of those with locoregional failure, ten were treated with salvage SBRT at a median time of 10 months from prior SBRT. Six patients were treated with systemic chemotherapy and 2 patients were offered palliative care. All patients treated with salvage SBRT remained controlled at a median time of 12 months. Treatment was well tolerated with 2 patients experiencing grade 2 pneumonitis, 1 patient experiencing grade 3 chest wall pain and 1 with rib fracture. OS was compared between 3 subgroups: no locoregional failure (n = 65), locoregional failure without SBRT salvage (n = 7) and locoregional failure with SBRT salvage (n = 10). The estimated median survival 31.3 months, 14.3 months and 29.9 months, respectively (p = 0.007). Conclusion:In our single institution patient cohort, SBRT in the salvage setting for locoregional recurrences after initial definitive SBRT for early-stage NSCLC is a potential option. Additional prospective data is needed.

show abstract

Stereotactic Body Radiation Therapy for Patients With Lung Cancer Previously Treated With Thoracic Radiation

Cited by 149 publications

References 26 publications

Salvage SBRT for Previously Irradiated Lung Cancer

Salvage SBRT for Previously Irradiated Lung Cancer

Stereotactic body radiotherapy (SBRT) for non- pathologically diagnosed lung cancer patients

Evaluating patterns of failure and salvage therapy for patients treated with primary stereotactic body radiation therapy for early stage non-small cell lung cancer

Contact Info

Product

Resources

About